S32 Translational Aspects in Neurological Diseases: from pathophysiology to new therapeutic approache
Ralf Linker (Regensburg) and Mathias Bähr (Göttingen)
Live Discussion: Tuesday, March 30, 2021, 18:00 – 19:00h
This symposium is organized by members of the German Neurological Society (DGN) in a collaborative effort of the NWG and the DGN. We will give insights into up-to-date research concepts on the neurobiology of classical neurological diseases. The ultimate aim is to delineate how advancing our understanding on disease pathophysiology may lead to the identification of new disease biomarkers or even to the generation of new treatment concepts for neurological disorders in a translational approach. The first presentation will center on new pathomechanisms in autoimmune encephalitis, where new target antigens and disease entities have been described only recently. Using single cell analyses, the talk will specifically address synaptic pathomechanisms of the disease. Following up on the role of the immune system in the central nervous system, the next presentation will analyze immunologically mediated mechanisms in the pathophysiology of Huntington’s disease as a classical genetically mediated neurodegenerative disorder.
The third presentation will again focus on neurodegeneration and show how new insights into the pathophysiology of Parkinson`s disease may pave the way to translate insights from disease etiology into new therapeutic concepts. The last talk will compare lesions in monkeys and humans that lead to impairments of spatial orientation and eye-hand coordination and add a strong focus on comparative cognitive neurology to the topic list. At the end of the symposium, there will be space for two presentations by young scientists.
Our symposium will fuel a better understanding of neurological diseases and foster interactions between neuroscientists and clinical neurologists thus aiming at the ultimate goal to overcome translational roadblocks in the much-needed research at the interface between the laboratory bench and the patient.
We gratefully acknowledge the financial support of Resolve Biosciences.